Previous close | 11.51 |
Open | 11.62 |
Bid | 11.80 x 7900 |
Ask | 11.84 x 15500 |
Day's range | 11.37 - 11.83 |
52-week range | 10.69 - 30.79 |
Volume | |
Avg. volume | 18,244,354 |
Market cap | 10.204B |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.74 |
Earnings date | 10 Oct 2024 - 14 Oct 2024 |
Forward dividend & yield | 1.00 (8.46%) |
Ex-dividend date | 21 Aug 2024 |
1y target est | 12.53 |
(Bloomberg) -- JPMorgan Chase & Co. is sounding out investors on a potential high-yield bond sale by Walgreens Boots Alliance Inc. to address the recently downgraded drug-store chain’s near-term debt maturities, according to people familiar with the matter. Most Read from BloombergTrump Risks Losing Voters He Needs With Loaded Attacks on HarrisHarris Just Showed Why Trump Is So Afraid of HerMarkets Tear Up Popular Trades That Reached ‘Stupid Levels’Stocks Caught in Tug of War Between Tech and Re
Q2 2024 Agree Realty Corp Earnings Call
DEERFIELD, Ill., July 23, 2024--Walgreens today announced it received a project award valued up to $25 million through the Rapid Response Partnership Vehicle (RRPV) to conduct a Phase IV observational clinical study focused on assessing Correlates of Protection (CoP), known as responses to a vaccine that predict how well a vaccinated person will be protected from future infections, using COVID-19 vaccine data. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Au